In the wake of a market pull in obesity nearly five years ago, the other shoe has dropped for Eisai’s serotonin 2C receptor ...

The decision in Europe follows an approval granted by the US Food and Drug Administration (FDA) in March this year.

In a new era of Alzheimer’s disease research, the emergence of blockbuster therapies like Eli Lilly’s Kisunla (donanemab) and ...

That Thursday, for the first time, the European Medicines Agency (EMA) approved a drug that targets the cause — not just the ...

AbbVie's $10.1 billion takeover of ImmunoGen has been rewarded with EU approval for Elahere, the first drug specifically ...

Allarity maintains a cash balance of $18.5 million, sufficient to advance and accelerate stenoparib's clinical development ...

The Sleep Research Society Foundation is hosting a state-of-the-science webinar, "Lessons Learned from Central Disorders of Hypersomnolence and Future Directions," Monday, Dec. 2, from 9:30 a.m. to 11 ...

We were all shocked when word slipped out that Jumana Murad was a married lady! The whole deal was very quick to come to pass ...

Biogen downgraded to Hold by Needham amid projected flat revenues until 2026. Leqembi and other new product sales show ...

Needham has downgraded Biogen (BIIB) to hold from buy, citing a lack of near-term catalysts and slow uptake for the company’s ...

Needham analyst Ami Fadia downgraded Biogen (BIIB) to Hold from Buy.Don't Miss our Black Friday Offers:Discover the latest stocks recommended ...

OPUVIZ is one of the first wave aflibercept biosimilars in Europe OPUVIZ is the second European Commission (EC)-approved ophthalmology biosimilar under Samsung Bioepis and Biogen's partnership EC ...